Clinical Trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Study acronym: TRIPL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-03-04; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2025-06-20
Trial Details
NCT Number NCT06865339
Lead Sponsor Montefiore Medical Center
Collaborators: Regeneron Pharmaceuticals, Henry Ford Health System, NYU Langone Health, University of Michigan
Conditions NSCLC, Locally Advanced
Enrollment 76 participants
Start Date 2025-08-07
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-13